Clinical Trial Update: Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating decitabine and arsenic trioxide for myelodysplastic syndromes with P53 mutation was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Decitabine (Decitabine)

Snippet

Sponsor: Li Junmin | Conditions: Myelodysplastic Syndromes, P53 Mutation | Phase 3 | Status: WITHDRAWN